317 related articles for article (PubMed ID: 15951353)
1. In vitro activity of tigecycline against Bacteroides species.
Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
[TBL] [Abstract][Full Text] [Related]
2. [Susceptibility of the Bacteroides fragilis group to 10 antibiotics. Results of 4 laboratories in Austria].
Mittermayer H; Rotter M; Riezinger F; Thiel W; Stanek G
Zentralbl Bakteriol Mikrobiol Hyg A; 1986 Nov; 262(4):500-11. PubMed ID: 3799095
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains.
Katsandri A; Avlamis A; Pantazatou A; Petrikkos GL; Legakis NJ; Papaparaskevas J;
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):231-6. PubMed ID: 16626904
[TBL] [Abstract][Full Text] [Related]
4. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibilities of Bacteroides fragilis and Bacteroides thetaiotaomicron strains isolated from clinical specimens and human intestinal microbiota.
Ulger Toprak N; Celik C; Cakici O; Soyletir G
Anaerobe; 2004 Oct; 10(5):255-9. PubMed ID: 16701525
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
9. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
[TBL] [Abstract][Full Text] [Related]
10. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.
Wybo I; Piérard D; Verschraegen I; Reynders M; Vandoorslaer K; Claeys G; Delmée M; Glupczynski Y; Gordts B; Ieven M; Melin P; Struelens M; Verhaegen J; Lauwers S
J Antimicrob Chemother; 2007 Jan; 59(1):132-9. PubMed ID: 17095529
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of tigecycline against the Bacteroides fragilis group.
Jacobus NV; McDermott LA; Ruthazer R; Snydman DR
Antimicrob Agents Chemother; 2004 Mar; 48(3):1034-6. PubMed ID: 14982803
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of antimicrobial resistance patterns of enterotoxin gene positive and negative Bacteroides fragilis isolates].
Toprak NU; Yağci A; Celik C; Cakici O; Söyletir G
Mikrobiyol Bul; 2005 Apr; 39(2):145-52. PubMed ID: 16128024
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Bacteroides fragilis, Bacteroides thetaiotaomicron, and Fusobacteria in Antibacterial agents.
Niederau W; Höffler U; Pulverer G
Arzneimittelforschung; 1980; 30(12):2093-8. PubMed ID: 7194067
[TBL] [Abstract][Full Text] [Related]
18. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
[TBL] [Abstract][Full Text] [Related]
19. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
Casal M; Rodríguez F; Johnson B; Garduno E; Tubau F; de Lejarazu RO; Tenorio A; Giménez MJ; Bartolomé R; Garcia-Rey C; Aguilar L; García-Escribano N
J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
[TBL] [Abstract][Full Text] [Related]
20. Resistance of Bacteroides isolates recovered among clinical samples from a major Costa Rican hospital between 2000 and 2008 to ß-lactams, clindamycin, metronidazole, and chloramphenicol.
Cordero-Laurent E; Rodríguez C; Rodríguez-Cavallini E; Gamboa-Coronado MM; Quesada-Gómez C
Rev Esp Quimioter; 2012 Dec; 25(4):261-5. PubMed ID: 23303257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
